An injection designed to tackle obesity could reduce the risk of heart attacks and strokes – regardless of how much weight they lose while on the drug, according to a new study.
Researchers looked at the effects of semaglutide – which is a prescription drug that suppresses appetite and is sold under the brand names Wegovy, Ozempic and Rybelsus.
They said the anti-obesity jabs could also benefit the cardiovascular health of millions of adults, with one researcher likening it to when statins were introduced in the 1990s.
Subscribe here: http://bit.ly/1rbfUog
For more news, analysis and features visit: www.bbc.com/news
#Ozempic #WeightLoss #BBCNews